alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
EXHIBIT
10.37


 





First Amendment
to Licensing Agreement


 


This First Amendment to
Licensing Agreement ("First Amendment") is to memorialize the agreement between PharmaCyte Biotech, Inc.,
formerly Nuvilex, Inc. ("Licensee"), and Austrianova Singapore Pte Ltd ("Licensor”)
to amend, effective as of 24 June 2016,
the Licensing Agreement between the parties entered into as of June 25th,
2013 ("Licensing Agreement") as follows.


 





	 	A.	The parties entered
into the Licensing Agreement to provide Licensee with an exclusive worldwide license to use the Cell-in-a-Box® Trademark and
its Associated Technology with genetically modified non-stem cell lines and IPS stem cells specifically designed to produce insulin
or other critical components for the treatment of diabetes to research, have made by Licensor, use in clinical trial, obtain market
approval, market and sell products and treatments utilizing the Cell-in-a-Box® Trademark and its Associated Technology world-wide;



 





	 	B.	Section 8.1.2.1. of the Licensing Agreement provides that if
Licensee does not enter into a research program with the technology in the scope of the license granted in the Licensing
Agreement involving European academic university partners providing a total funding equal to or greater than US $400,000.00
within three year of the effective date of the Licensing Agreement, Licensor has the right to terminate the Licensing Agreement
on the condition that Licensor provide Licensee 30 days' notice
and the opportunity to cure Licensee's failure to meet this milestone event; and



 





	 	C.	The Parties desire
to amend the provisions of Section 8.1.2.1. to expand the scope
of the research program to include countries world-wide and not require the research program be limited to academic university
partners.



 


NOW,
THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged by the
Parties, the Research Agreement is hereby amended as follows:


 


1.  
Section 8.1.2.1. of the Licensing Agreement shall be deleted
and the following inserted in its place: "If LICENSEE does not enter into a research program with the technology in the scope
of the License providing a total funding equal to or greater than Four Hundred Thousand Dollars US (US $400,000.00)
within three (3) years of the Effective Date; or"


 


2.  
Except as provided in this First Amendment, all of the other provisions of the Licensing Agreement shall remain in full
force and effect.


 


IN
WITNESS WHEREOF, each party to the Licensing Agreement has executed this First Amendment by its duly authorized representative
as of the date first written above.


 





	PharmaCyte Biotech, Inc.	Austrianova
Singapore Pte Ltd
	 	 
	/s/ Kenneth L. Waggoner               	/s/ Brian Salmons              
	By: Dr. Kenneth L. Waggoner

                                    Title:
Chief Executive Officer

                                    
	By:

        Title:
	Dr. Brian Salmons
 Chief
Executive Officer
STATE v. MCINTOSH.

No. COA06-1441.

Court of Appeals of North Carolina.

Filed September 4, 2007.

Certification Date September 24, 2007.

Appeal from Davidson (05CRS4862, 05CRS52157, 05CRS52158).

Case reported without published opinion No error.
Exhibit 31.1
**CERTIFICATION**
I, Robert W. O’Leary, Chief Executive Officer, certify that:
     1. Ihave reviewed this quarterly report on Form 10-Q of ValeantPharmaceuticals International;
     2. Based on my knowledge, this report does not contain any untruestatement of a material fact or omit to state a material fact necessary to makethe statements made, in light of the circumstances under which such statementswere made, not misleading with respect to the period covered by this report;
     3. Based on my knowledge, the financial statements, and other financialinformation included in this report, fairly present in all material respectsthe financial condition, results of operations and cash flows of the registrantas of, and for, the periods presented in this report;
          4. The registrant’s other certifying officer(s) and I are responsible forestablishing and maintaining disclosure controls and procedures (as defined inExchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:
          (a) Designed such disclosure controls and procedures, or caused suchdisclosure controls and procedures to be designed under our supervision, toensure that material information relating to the registrant, including itsconsolidated subsidiaries, is made known to us by others within those entities,particularly during the period in which this report is being prepared;
          (b) Evaluated the effectiveness of the registrant’s disclosure controlsand procedures and presented in this report our conclusions about theeffectiveness of the disclosure controls and procedures, as of the end of theperiod covered by this report based on such evaluation; and
          (c) Disclosed in this report any change in the registrant’s internalcontrol over financial reporting that occurred during the registrant’s mostrecent fiscal quarter (the registrant’s fourth fiscal quarter in the case of anannual report) that has materially affected, or is reasonably likely tomaterially affect, the registrant’s internal control over financial reporting;and
     5. The registrant’s other certifying officer(s) and I have disclosed,based on our most recent evaluation of internal control over financialreporting, to the registrant’s auditors and the audit committee of registrant’sboard of directors (or persons performing the equivalent functions):
          (a) All significant deficiencies and material weaknesses in the design oroperation of internal control over financial reporting which are reasonablylikely to adversely affect the registrant’s ability to record, process,summarize and report financial information; and
          (b) Any fraud, whether or not material, that involves management or otheremployees who have a significant role in the registrant’s internal control overfinancial reporting.        Date: August 9, 2004/s/ ROBERT W. O'LEARY   **Robert W. O'Leary**   **Chairman of the Board and Chief Executive Officer**
EXHIBIT 99.3
                                                                    ------------



In connection with the Annual Report of Compton Petroleum Corporation (the
"Company") on Form 40-F for the period ended December 31, 2002 (the "Report") to
which this certificate is an exhibit, I, Ernest G. Sapieha, President and Chief
Executive Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section
1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002,
that:

1.       The Report fully complies with the requirements of Section 13(a) or
         15(d) of the Securities Exchange Act of 1934; and

2.       The information contained in the Report fairly presents, in all
         material respects, the financial condition and results of operations of
         the Company.


Date:  May 9, 2003                                /s/ Ernest G. Sapieha
                                                  ------------------------------
                                                  Ernest G. Sapieha
                                                  President and Chief Executive
                                                  Officer



A signed original of this written statement required by Section 906 has been
provided to Compton Petroleum Corporation and will be retained by Compton
Petroleum Corporation and furnished to the Securities and Exchange Commission or
its staff upon request.
# Commission Regulation (EU) No 873/2013Show full title

Commission Regulation (EU) No 873/2013 of 11 September 2013 establishing a prohibition of fishing for saithe in areas IIIa            and IV; EU waters of IIa, IIIb, IIIc and Subdivisions 22-32 by vessels flying the flag of the Netherlands         

        - Previous
        - Next

U.K.

# Commission Regulation (EU) No 873/2013                     

# of 11 September 2013

# establishing a prohibition of fishing for saithe in areas IIIa and IV; EU waters of IIa, IIIb, IIIc and Subdivisions 22-32                        by vessels flying the flag of the Netherlands                     

THE EUROPEAN COMMISSION,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Council Regulation (EC) No 1224/2009 of 20 November 2009 establishing a Community control system for ensuring                           compliance with the rules of the common fisheries policy(1), and in particular Article 36(2) thereof,                        

Whereas:

(1)Council Regulation (EU) No 40/2013 of 21 January 2013 fixing for 2013 the fishing opportunities available in EU waters and,                              to EU vessels, in certain non-EU waters for certain fish stocks and groups of fish stocks which are subject to international                              negotiations or agreements(2), lays down quotas for 2013.

(2)According to the information received by the Commission, catches of the stock referred to in the Annex to this Regulation                              by vessels flying the flag of or registered in the Member State referred to therein have exhausted the quota allocated for                              2013.

(3)It is therefore necessary to prohibit fishing activities for that stock,

HAS ADOPTED THIS REGULATION:

## Article 1U.K.Quota exhaustion

The fishing quota allocated to the Member State referred to in the Annex to this Regulation for the stock referred to therein                     for 2013 shall be deemed to be exhausted from the date set out in that Annex.                  

## Article 2U.K.Prohibitions

Fishing activities for the stock referred to in the Annex to this Regulation by vessels flying the flag of or registered in                     the Member State referred to therein shall be prohibited from the date set out in that Annex. In particular it shall be prohibited                     to retain on board, relocate, tranship or land fish from that stock caught by those vessels after that date.                  

## Article 3U.K.Entry into force

This Regulation shall enter into force on the day following that of its publication in the *Official Journal of the European Union*.                  

This Regulation shall be binding in its entirety and directly applicable in all Member States.

Done at Brussels, 11 September 2013.

*For the Commission, On behalf of the President*,                           

Lowri Evans                            

*Director-General for Maritime Affairs and Fisheries*                            

## ANNEXU.K.

1

OJ L 343, 22.12.2009, p. 1.                           

2

OJ L 23, 25.1.2013, p. 54.
I 

110TH CONGRESS 

2D SESSION S. 3658 

IN THE HOUSE OF REPRESENTATIVES 

OCTOBER 2, 2008 

Referred to the Committee on the Judiciary 

AN ACT 

To require the accreditation of English language training 

programs, and for other purposes. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 


pwalker on PROD1PC71 with BILLS
2 

S 3658 RFH

1 SECTION 1. ACCREDITATION OF ENGLISH LANGUAGE 

2 TRAINING PROGRAMS. 

3 (a) IN GENERAL.—Section 101(a) of the Immigra4 tion and Nationality Act (8 U.S.C. 1101(a)) is amended— 

5 (1) in paragraph (15)(F)(i), by striking ‘‘a lan6 guage’’ and inserting ‘‘an accredited language’’; and 

7 (2) by adding at the end the following: 

8 ‘‘(52) The term ‘accredited language training pro9 gram’ means a language training program that is accred10 ited by an accrediting agency recognized by the Secretary 

11 of Education.’’. 

12 (b) EFFECTIVE DATE.— 

13 (1) IN GENERAL.—Except as provided in para14 graph (2), the amendments made by subsection (a) 

15 shall— 

16 (A) take effect on the date that is 180 

17 days after the date of the enactment of this 

18 Act; and 

19 (B) apply with respect to applications for 

20 a nonimmigrant visa under section 

21 101(a)(15)(F)(i) of the Immigration and Na22 tionality Act (8 U.S.C. 1101(a)(15)(F)(i)) that 

23 are filed on or after the effective date described 

24 in subparagraph (A). 

25 (2) TEMPORARY EXCEPTION.— 


pwalker on PROD1PC71 with BILLS
3 

S 3658 RFH

1 (A) IN GENERAL.—Notwithstanding sec2 tion 101(a)(15)(F)(i) of the Immigration and 

3 Nationality Act, as amended by subsection (a), 

4 during the 3-year period beginning on the date 

5 of the enactment of this Act, an alien seeking 

6 to enter the United States to pursue a course 

7 of study at a language training program that 

8 has been certified by the Secretary of Home9 land Security and has not been accredited or 

10 denied accreditation by an entity described in 

11 section 101(a)(52) of such Act may be granted 

12 a nonimmigrant visa under such section 

13 101(a)(15)(F)(i). 

14 (B) ADDITIONAL REQUIREMENT.—An 

15 alien may not be granted a nonimmigrant visa 

16 under subparagraph (A) if the sponsoring insti17 tution of the language training program to 

18 which the alien seeks to enroll does not— 

19 (i) submit an application for the ac20 creditation of such program to a regional 

21 or national accrediting agency recognized 

22 by the Secretary of Education within 1 

23 year after the date of the enactment of this 

24 Act; and 


pwalker on PROD1PC71 with BILLS
4 

S 3658 RFH

1 (ii) comply with the applicable accred2 iting requirements of such agency. 

Passed the Senate September 30 (legislative day, 

September 17), 2008. 

Attest: NANCY ERICKSON, 

Secretary. 


pwalker on PROD1PC71 with BILLS
```

[Congressional Bills 110th Congress]
[From the U.S. Government Publishing Office]
[S. 3568 Introduced in Senate (IS)]

110th CONGRESS
  2d Session
                                S. 3568

     To amend the Controlled Substances Act to address the use of 
                           intrathecal pumps.

_______________________________________________________________________

                   IN THE SENATE OF THE UNITED STATES

           September 24 (legislative day, September 17), 2008

  Mr. Cornyn introduced the following bill; which was read twice and 
               referred to the Committee on the Judiciary

_______________________________________________________________________

                                 A BILL

 
     To amend the Controlled Substances Act to address the use of 
                           intrathecal pumps.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. INTRATHECAL PUMPS.

    Section 102(10) of the Controlled Substances Act (21 U.S.C. 
802(10)) is amended--
            (1) by striking ``The term `dispense' means to deliver'' 
        and inserting the following: ``(A) The term `dispense' means--
            ``(i) to deliver'';
            (2) by striking ``such delivery.'' and inserting the 
        following: ``such delivery; or
            ``(ii) to deliver a controlled substance by a pharmacy to a 
        practitioner, pursuant to the prescription of the practitioner, 
        where such controlled substance is to be administered through 
        the use of an intrathecal pump by the practitioner acting in 
        the usual course of professional practice.'';
            (3) by striking ``The term `dispenser' means'' and 
        inserting the following:
    ``(B) The term `dispenser' means''; and
            (4) by striking ``to an ultimate user or research 
        subject''.
                                 <all>
```
IN RE S.S.S.

No. COA07-751.

Court of Appeals of North Carolina.

Filed December 18, 2007

Certification Date January 7, 2008.

Appeal from Cleveland (06JA76, 06JA77).

Decision without published opinion. Affirmed.
<TABLE> <S> <C>


<ARTICLE> 5
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   12-MOS
<FISCAL-YEAR-END>                          DEC-31-1999
<PERIOD-START>                             JAN-01-1999
<PERIOD-END>                               DEC-31-1999
<CASH>                                         494,301
<SECURITIES>                                 1,419,762
<RECEIVABLES>                                  644,269
<ALLOWANCES>                                    44,556
<INVENTORY>                                     86,583
<CURRENT-ASSETS>                             2,830,571
<PP&E>                                       2,414,731
<DEPRECIATION>                                 265,268
<TOTAL-ASSETS>                               6,377,867
<CURRENT-LIABILITIES>                          982,089
<BONDS>                                      2,970,644
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                         4,636
<OTHER-SE>                                   2,107,964
<TOTAL-LIABILITY-AND-EQUITY>                 6,377,867
<SALES>                                              0
<TOTAL-REVENUES>                             2,022,996
<CGS>                                                0
<TOTAL-COSTS>                                1,705,181
<OTHER-EXPENSES>                                35,143
<LOSS-PROVISION>                                28,390
<INTEREST-EXPENSE>                             136,730
<INCOME-PRETAX>                              (367,472)
<INCOME-TAX>                                   (7,771)
<INCOME-CONTINUING>                          (359,701)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 (359,701)
<EPS-BASIC>                                     (0.87)
<EPS-DILUTED>                                   (0.87)


</TABLE>
EXHIBIT 32.1
                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                 SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of OraLabs Holding Corp. (the "Company") on
Form 10-KSB/A for the period ending December 31, 2004 as filed with the
Securities and Exchange Commission on the date hereof (the "Report") I, Emile
Jordan, Chief Financial Officer of the Company, certify, pursuant to 18 USC SS.
1350, as adopted pursuant to SS. 906 of the Sarbanes-Oxley Act of 2002, that to
the best of my knowledge and belief:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of
the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material
respects, the financial condition and results of operations of the Company.





/S/ EMILE JORDAN
-------------------------------------
EMILE JORDAN, CHIEF FINANCIAL OFFICER



DATED: DECEMBER 21, 2005
##### 



EXHIBIT 99.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER
PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Vicente Anido, Jr., Ph.D., certify, pursuant to 18 U.S.C. Section 1350, as
adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the
Quarterly Report of ISTA Pharmaceuticals, Inc. on Form 10-Q for the quarterly
period ended June 30, 2002 fully complies with the requirements of Section
13(a) or 15(d) of the Securities Exchange Act of 1934 and that information
contained in such Form 10-Q fairly presents in all material respects the
financial condition and result of operations of ISTA Pharmaceuticals, Inc.

| |  |                                                                                               
| |  | ----------------------------------------------------------------------------------------------
| |  | /s/ Vicente Anido, Jr., Ph.D.

Vicente Anido, Jr., Ph.D.
Chief Executive Officer and President

I, David R. Waltz, certify, pursuant to 18 U.S.C. Section 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly
Report of ISTA Pharmaceuticals, Inc. on Form 10-Q for the quarterly period
ended June 30, 2002 fully complies with the requirements of Section 13(a) or
15(d) of the Securities Exchange Act of 1934 and that information contained in
such Form 10-Q fairly presents in all material respects the financial condition
and result of operations of ISTA Pharmaceuticals, Inc.

| |  |                                                           
| |  | ----------------------------------------------------------
| |  | /s/ David R. Waltz

David R. Waltz
Vice President, Finance

21
BROWN v. BROWN.

No. COA06-682.

Court of Appeals of North Carolina.

Filed January 15, 2008.

Certification Date February 4, 2008.

Appeal from Mecklenburg (03CVD3161).

Case reported without published opinion. Affirmed in part; and remanded in part.
EXHIBIT 21



       PETER KIEWIT SONS', INC. AND SUBSIDIARIES
                      March 17, 2000


Bell Cement Tools, L.L.C.
Ben Holt Company
Bentson Contracting Company
Bibb and Associates, Inc.
Construcciones Kiewit, S.A. de C.V.
Constructora Kiewit, C.A.
GBV-Texas, L.P.
GMF 1 L.L.C.
Gilbert/CBE Indonesia L.L.C.
Gilbert Central Corp.
Gilbert Frontier, Inc.
Gilbert Industrial Corporation
Gilbert Marine L.L.C.
Gilbert Network Services, L.P.
Gilbert Southern Corp.
Gilbert Texas Construction Corp.
Gilbert Western Corp.
Global Surety & Insurance Co.
Guernsey Construction Company
Guernsey Stone Company
Gulf Marine Fabricators, Inc.
Gulf Maritime, L.P.
Kiewit Alabama Mining Company
Kiewit Construction Company
Kiewit Construction Group Inc.
Kiewit Constructors Inc.
Kiewit Engineering Co.
Kiewit Engineering Canada Ltd.
Kiewit Financial Services B.V.
Kiewit/Holt Indonesia L.L.C.
Kiewit/Holt Philippines, L.P.
Kiewit Industrial Co.
Kiewit Industrial Canada Ltd.
Kiewit International Inc.
Kiewit International Services Inc.
Kiewit International Services Ltd.
Kiewit Investment Management Corp.
Kiewit Management Limited
Kiewit Materials Company
Kiewit Materials Leasing L.L.C.
Kiewit Mazon Constructores, S.A. de C.V.
Kiewit Mining Group Inc.
Kiewit Mining Services Inc.
Kiewit Network Services Co.
Kiewit Pacific Co.
Kiewit Pipelines Ltd.
Kiewit Venezuela Inc.
Kiewit Western Co.
Lac De Gras Excavation Inc.
Les Entreprises Kiewit Ltee
Mass. Electric Construction Co.
Mass. Electric Securities Corp., Inc.
ME Holding Inc.
MECC Rail Mexicana, S.A. de C.V.
Metro Concrete Pumping Company
Midwest Agencies, Inc.
MIL Offshore Inc.
Newsham Hybrids (USA), Inc.
Northwest Materials Holding Company
PT Kiewit International
Pacific Rock Products, L.L.C.
Pacific Rock Products Trucking, L.L.C.
Peter Kiewit Sons Co. Ltd.
Quality Ready Mix, Inc.
Servitec de Sonora, S.A. de C.V.
Solano Concrete Co., Inc.
Tanner Companies (Yuma) Inc.
Twin Mountain Construction Company
Twin Mountain Construction II Company
Twin Mountain Rock Company
United Metro Materials Inc.
V.K. Mason Construction Ltd.
V.K. Mason Inc.
Western Equipment Co.
A.J. LANCASTER, Jr. v. NORTH CAROLINA DEPARTMENT OF ENVIRONMENT AND NATURAL RESOURCES, Division of Waste Management, and Environmental Management Commission.

No. 591P07.

Supreme Court of North Carolina.

March 6, 2008.

Kathleen Waylett, Special Deputy Attorney General, for NCDENR, et al.

Lars P. Simonsen, Edenton, for Lancaster.

Prior report: ___ N.C.App. ___, 652 S.E.2d 359.

*ORDER*

Upon consideration of the petition filed on the 11th day of December 2007 by Respondents in this matter for discretionary review of the decision of the North Carolina Court of Appeals pursuant to G.S. 7A-31, the following order was entered and is hereby certified to the North Carolina Court of Appeals:

"Denied by order of the Court in conference, this the 6th day of March 2008."
In re J.J.

No. 15A07.

Supreme Court of North Carolina.

July 24, 2007.

Jil Sanchez, for Gaston County DSS.

Laura Crawford, for Perry Bobbin.

*442Ed Bogle, for Guardian Ad Litem.

Wendy C. Sotolongo, Durham, for Mother.

The following order has been entered on the motion filed on the 23rd day of July 2007 by Respondent to Withdraw as Counsel:

"Motion Allowed by order of the Court in conference this the 24th day of July 2007."

HUDSON, J., recused.